Taysha Gene Therapies Inc reported that it has initiated an underwritten public offering of its common stock and pre-funded warrants, describing the proposed raise as $200 million in combined securities. The company said the announcement was followed by an 8.5% decline in its shares during after-hours trading on Wednesday.
According to the company, all securities in the proposed transaction will be offered directly by Taysha. In addition to the primary offering, the company plans to grant the underwriting syndicate a 30-day option to purchase up to an additional 15% of the shares included in the public offering, a provision that explicitly includes shares underlying the pre-funded warrants. Taysha noted that the offering is subject to market conditions.
The underwriting group named in the filing consists of Jefferies, Goldman Sachs & Co. LLC, Piper Sandler and Cantor as joint book-running managers, while Baird is identified as the lead manager for the transaction.
Taysha described its corporate focus as advancing adeno-associated virus - based gene therapies targeted at severe monogenic diseases of the central nervous system. The company's statement did not provide additional operational or financial details beyond the structure of the proposed offering and the participation of the listed underwriters.
For market participants, the company-provided details are limited to the offering mechanics and the named managers. The filing highlights two structural features that may affect the ultimate size and timing of the transaction - the 30-day option for additional shares and the condition that the offering depends on prevailing market conditions.
Investors and observers should note that the company framed the securities as common stock and pre-funded warrants, and that all of the securities are to be sold by Taysha. No further terms, pricing information or intended use of proceeds were included in the announcement.
The company's description of its business activities remains focused on developing adeno-associated virus-based gene therapies for severe monogenic conditions affecting the central nervous system. The public statement did not include forecasts, target indications, or timelines related to its clinical programs.
As presented by the company, the proposed offering is contingent on market conditions and includes the potential for the underwriting group to expand the offering by up to 15% within a 30-day window. The announcement coincided with the after-hours trading decline noted above.